Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chufeng Zhang

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Nature Communications|October 8, 2022
Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAKChenxu Ge, Jun Tan, Xianling Dai, et al.
Journal of Medicinal Chemistry|February 16, 2021
Correction to "<i>N</i>-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms"Tao Yang, Mengshi Hu, Yong Chen, et al.
Journal of Medicinal Chemistry|November 1, 2019
Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative NeoplasmsTao Yang, Mengshi Hu, Wenyan Qi, et al.
Journal of Medicinal Chemistry|January 28, 2020
Correction to "Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms"Tao Yang, Mengshi Hu, Wenyan Qi, et al.
Journal of Medicinal Chemistry|December 1, 2020
<i>N</i>-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative NeoplasmsTao Yang, Mengshi Hu, Yong Chen, et al.
Journal of Medicinal Chemistry|June 17, 2021
Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory DiseasesKongjun Liu, Dan Li, Wei Zheng, et al.
European Journal of Medicinal Chemistry|April 19, 2026
Structure-based design and synthesis of KX-01 analogs as potent antitumor agents targeting the tubulin colchicine binding siteChufeng Zhang, Yilin Wang, Chenke Gao, et al.
Journal of Medicinal Chemistry|July 13, 2022
Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell MalignanciesKongjun Liu, Wei Zheng, Yong Chen, et al.
Bioorganic Chemistry|January 26, 2023
Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitorsYong Guo, Yurong Zou, Yong Chen, et al.
Journal of Medicinal Chemistry|December 20, 2023
Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of MalignanciesKongjun Liu, Xue Yuan, Tao Yang, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Nature Communications|October 8, 2022
Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAKChenxu Ge, Jun Tan, Xianling Dai, et al.
Journal of Medicinal Chemistry|February 16, 2021
Correction to "<i>N</i>-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms"Tao Yang, Mengshi Hu, Yong Chen, et al.
Journal of Medicinal Chemistry|November 1, 2019
Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative NeoplasmsTao Yang, Mengshi Hu, Wenyan Qi, et al.
Journal of Medicinal Chemistry|January 28, 2020
Correction to "Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms"Tao Yang, Mengshi Hu, Wenyan Qi, et al.
Journal of Medicinal Chemistry|December 1, 2020
<i>N</i>-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative NeoplasmsTao Yang, Mengshi Hu, Yong Chen, et al.
Journal of Medicinal Chemistry|June 17, 2021
Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory DiseasesKongjun Liu, Dan Li, Wei Zheng, et al.
European Journal of Medicinal Chemistry|April 19, 2026
Structure-based design and synthesis of KX-01 analogs as potent antitumor agents targeting the tubulin colchicine binding siteChufeng Zhang, Yilin Wang, Chenke Gao, et al.
Journal of Medicinal Chemistry|July 13, 2022
Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell MalignanciesKongjun Liu, Wei Zheng, Yong Chen, et al.
Bioorganic Chemistry|January 26, 2023
Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitorsYong Guo, Yurong Zou, Yong Chen, et al.
Journal of Medicinal Chemistry|December 20, 2023
Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of MalignanciesKongjun Liu, Xue Yuan, Tao Yang, et al.
Pageof 5